Abstracts tagged "systemic lupus erythematosus (SLE) and treatment"

Abstract Number: 665 • 2014 ACR/ARHP Annual Meeting
Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus
Jing He¹, Xia Zhang², Xiaolin Sun³, Jianping Guo³, Yunbo Wei⁴, Zhaohua Hou⁴, Yu Di⁵ and Zhanguo Li³, ¹Department of Rheumatology & Immunology, Peking University People's Hospital, Beijing, China, ²Department of Rheumatology & immunology, Peking University People's Hospital, Beijing, China, ³Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ⁴Immunology for Environment and Health, Shandong Analysis and Test Center, Shandong Academy of Science, Shandong, China, ⁵Molecular Immunomodulation Laboratory, Monash University, Clayton, Austria
Background/Purpose Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by loss of tolerance to nuclear self-antigens, production of pathogenic autoantibodies and damage tomultiple organs.…
Abstract Number: 589 • 2013 ACR/ARHP Annual Meeting
A Survey Of Physician and Patient Satisfaction With Control Of Systemic Lupus Erythematosus and Lupus Nephritis
Neelufar Mozaffarian¹, Steve Lobosco² and Adam Roughley², ¹AbbVie, North Chicago, IL, ²Adelphi Real World Ltd., Macclesfield, United Kingdom
Background/Purpose: Patient satisfaction with disease control is an important component of overall health and well-being. Current treatment options for systemic lupus erythematosus (SLE) ±lupus nephritis…
Abstract Number: 579 • 2013 ACR/ARHP Annual Meeting
Switching Treatment Between Mycophenolate Mofetil and Azathioprine In Lupus Patients The Reasons and The Effect
Hesham Al Maimouni, Dafna D. Gladman, Dominique Ibanez and Murray B. Urowitz, Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Disease activity in systemic lupus erythematosus is an important predictor of subsequent organ damage and mortality from lupus. However, the optimal agent for chronic…
Abstract Number: 2530 • 2013 ACR/ARHP Annual Meeting
Sustained Improvements In Health-Related Quality Of Life In Patients With Systemic Lupus Erythematosus following Epratuzumab Treament: Results from a Phase IIb Trial and Its Open-Label Extension
Vibeke Strand¹, Joan T. Merrill², Enkeleida Nikaï³, Brian Kilgallen⁴, Antoine Regnault⁵ and Caroline Gordon⁶, ¹Stanford University, Palo Alto, CA, ²Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³UCB Pharma, Brussels, Belgium, ⁴UCB Pharma, Raleigh, NC, ⁵Mapi HEOR & Strategic Market Access, Lyon, France, ⁶Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Epratuzumab is a monoclonal antibody targeting CD22. Improvements in health-related quality of life (HRQoL) with epratuzumab in patients with systemic lupus erythematosus (SLE) have…
Abstract Number: 1807 • 2013 ACR/ARHP Annual Meeting
Do We Know How and When To Taper and Stop In Immunosuppressants In Lupus Patients?
Zahi Touma¹, Murray B. Urowitz², Dominique Ibanez² and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: After achieving low disease activity or remission, immunosuppressant therapies might be stopped in lupus patients, but information on whether and how this should be…
Abstract Number: 1738 • 2013 ACR/ARHP Annual Meeting
Epratuzumab Maintains Improvements In Disease Activity For Over 2 Years In Patients With Moderate-To-Severe Systemic Lupus Erythematosus: Results From An Open-Label Long-Term Extension Study
Megan E. B. Clowse¹, Frederic Houssiau², Michelle A. Petri³, Brian Kilgallen⁴, Kenneth Kalunian⁵, Vibeke Strand⁶, Sabine Bongardt⁷, Caroline Gordon⁸ and Daniel J. Wallace⁹, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Department of Rheumatology, Université catholique de Louvain, Brussels, Belgium, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴UCB Pharma, Smyrna, GA, ⁵UCSD School of Medicine, La Jolla, CA, ⁶Stanford University, Palo Alto, CA, ⁷UCB Pharma, Brussels, Belgium, ⁸Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, ⁹Rheumatology, Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Epratuzumab is a monoclonal antibody targeting CD22. In EMBLEMTM (dose-ranging phase IIb study), epratuzumab produced clinically relevant improvements in disease activity in patients…
Abstract Number: 1739 • 2013 ACR/ARHP Annual Meeting
Sustained British Isles Lupus Assessment Group-Measured Improvement In Moderately-and-Severely Affected Body Systems In Patients With Systemic Lupus Erythematosus By Epratuzumab: Results From An Open-Label Extension Study
Kenneth Kalunian¹, Megan E. B. Clowse², Frederic Houssiau³, Michelle A. Petri⁴, Brian Kilgallen⁵, Caroline Gordon⁶, Vibeke Strand⁷, Sabine Bongardt⁸ and Daniel J. Wallace⁹, ¹UCSD School of Medicine, La Jolla, CA, ²Rheumatology, Duke University Medical Center, Durham, NC, ³Department of Rheumatology, Université catholique de Louvain, Brussels, Belgium, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵UCB Pharma, Raleigh, NC, ⁶Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, ⁷Stanford University, Palo Alto, CA, ⁸UCB Pharma, Brussels, Belgium, ⁹Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Epratuzumab is a monoclonal antibody targeting CD22. In EMBLEMTM (a dose-ranging phase IIb study), epratuzumab produced clinically relevant improvements in disease activity in patients…
Abstract Number: 1606 • 2013 ACR/ARHP Annual Meeting
Overview Of The Safety Of Epratuzumab In Systemic Lupus Erythematosus
Daniel J. Wallace¹, Josep Ordi-Ros², C. Michael Neuwelt³, Kenneth Kalunian⁴, Michelle A. Petri⁵, Slawomir Jeka⁶, Ronald F. van Vollenhoven⁷, Brian Kilgallen⁸, Sabine Bongardt⁹, Caroline Gordon¹⁰ and Vibeke Strand¹¹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Internal Medicine, Vall De Hebron General Hospt, Barcelona, Spain, ³East Bay Rheumatology Research Institute, San Leandro, CA, ⁴UCSD School of Medicine, La Jolla, CA, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶2nd University Hospital in Bydgoszcz Medical College of Nicolaus Copernicus University, Bydgoszcz, Poland, ⁷Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Brussels, Belgium, ¹⁰Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, ¹¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: The efficacy and safety of epratuzumab, a monoclonal antibody targeting CD22, has been evaluated in patients with moderate-to-severe systemic lupus erythematosus (SLE). A pooled…
Abstract Number: 1588 • 2013 ACR/ARHP Annual Meeting
Poor Adherence To Medications For Systemic Lupus Erythematosus Among U.S. Medicaid Beneficiaries
Jinoos Yazdany¹, Jun Liu², Graciela S. Alarcon³, Karen H. Costenbader⁴ and Candace H. Feldman⁵, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, Boston, CA, ³Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Immunosuppressive and anti-malarial drugs are the cornerstones of treatment for patients with systemic lupus erythematosus (SLE) and have been shown to improve outcomes,…
Abstract Number: 1561 • 2013 ACR/ARHP Annual Meeting
Treat-To-Target In Systemic Lupus Erythematosus: Report From the T2T/SLE Working Party
Ronald F. van Vollenhoven¹, Marta Mosca², George Bertsias³, Annegret Kuhn⁴, Kirsten Lerstrøm⁵, Josef S. Smolen⁶, David A. Isenberg⁷, Matthias Schneider⁸ and the T2T/SLE Working Party⁹, ¹Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden, ²I, Rheumatology Unit, Internal Medicine, University of Pisa, Pisa, Italy, ³Rheumatology, Clinical Immunology, and Allergy, University of Crete, Heraklion, Greece, ⁴University of Münster, Münster, Germany, ⁵Lupus Europe, Farum, Denmark, ⁶Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁷Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁸Department of Endocrinology, Diabetes and Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, ⁹the Karolinska Institute, Stockholm, Sweden
Background/Purpose: The principle of treating-to-target has been applied successfully to many diseases outside rheumatology and more recently to rheumatoid arthritis. Identifying appropriate therapeutic targets and…
Abstract Number: 582 • 2013 ACR/ARHP Annual Meeting
A Real-World Survey Of Clinical Practice Among Rheumatologists and Nephrologists In The United States Reveals Differences In Care Of Non-Nephritis Systemic Lupus Erythematosus and Lupus Nephritis As Compared With American College Of Rheumatology Treatment Guidelines
Neelufar Mozaffarian¹, Steve Lobosco² and Adam Roughley², ¹AbbVie, North Chicago, IL, ²Adelphi Real World Ltd., Macclesfield, United Kingdom
Background/Purpose: Current pharmacotherapy for systemic lupus erythematosus (SLE) and lupus nephritis (LN) includes combinations of nonsteroidal anti–inflammatory drugs (NSAIDs), antimalarials (AMs), glucocorticoids (GCs), and cytotoxic…
Abstract Number: 2259 • 2012 ACR/ARHP Annual Meeting
Limitations of Current Treatment for Systemic Lupus Erythematosus: A Patient and Physician Survey
V. Strand¹, C. Galateanu², S. Lobosco³, D.S. Pushparajah², J. Sayers⁴ and R.F. van Vollenhoven⁵, ¹Stanford University, Portola Valley, CA, ²UCB Pharma, Brussels, Belgium, ³Adelphi Real World Ltd., Macclesfield, United Kingdom, ⁴Adelph Real World Ltd., Macclesfield, United Kingdom, ⁵Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Current SLE treatment regimens follow an ‘add-on' paradigm: typically, therapies are added as the activity of a patient's disease increases. Most current treatments, particularly…
Abstract Number: 1448 • 2012 ACR/ARHP Annual Meeting
Inhibition of Calcium/Calmodulin-Dependent Protein Kinase IV Suppresses the Autoimmunity in Lupus-Prone Mice
Kunihiro Ichinose¹, Atsushi Kawakami² and George C. Tsokos³, ¹Department of Immunology and Rheumatology, Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA
Inhibition of Calcium/Calmodulin-Dependent Protein Kinase IV Suppresses the Autoimmunity in Lupus-Prone Mice. Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease associated with abnormal…
Abstract Number: 1420 • 2012 ACR/ARHP Annual Meeting
Ethnicity and B Cell Depletion Therapy in Systemic Lupus Erythematosus
A. Lois-Iglesias¹, J. Ishorari² and D.A. Isenberg², ¹Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain. University College London, London, United Kingdom, ²Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose:The aim of this study was to determine if there is any relation between ethnicity and outcome in patients with SLE treated with B cell…
Abstract Number: 1421 • 2012 ACR/ARHP Annual Meeting
Antimalarials Protect Systemic Lupus Erythematosus Patients From Damage Accrual During the First Five Years of the Disease
Ioana Ruiz-Arruza¹, D. D. Gladman¹, Dominique Ibanez² and Murray B. Urowitz², ¹Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Studies in the last 20 years have demonstrated that antimalarials (AM) prevent flares, protect from damage accrual, reduce the risk of thrombosis and increase…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].